Fabio Alessandro Facchini

Fabio Alessandro Facchini

Auto-generated profile, based on publicly available information

Fabio Alessandro Facchini

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 2, 20126 Milano, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FFFabio Alessandro Facchini
Fabio Alessandro Facchini
LZLenny Zaffaroni
Lenny Zaffaroni
AMAlberto Minotti
Alberto Minotti
SRSilvia Rapisarda
Silvia Rapisarda
VCValentina Calabrese
Valentina Calabrese
FPFrancesco Peri
Francesco Peri
The structure-activity relationship was investigated in a series of synthetic TLR4 antagonists formed by a glucosamine core linked to two phosphate esters and two linear carbon chains. Molecular modeling showed that the compounds with 10, 12 and 14 carbons chains are associated to higher stabilization of the TLR4/MD-2 antagonist conformation than in the case of the C16 variant. Binding experiments with human MD-2 showed that the C12 and C14 variants have higher affinity than C10, while the C16 variant did not interact with the protein. The molecules, with the exception of the C16 variant, inhibited the LPS-stimulated TLR4 signal in human and murine cells and the antagonist potency mirrored the MD-2 affinity calculated from in vitro binding experiments. FT-IR, NMR, and SAXS measurements suggested that the aggregation state in aqueous solution depends on fatty acid chains lengths and that this property can influence TLR4 activity in this series of compounds.

15 February 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CGChiara Grasselli
Chiara Grasselli
DFDaniela Ferrari
Daniela Ferrari
CZCristina Zalfa
Cristina Zalfa
MSMatias Soncini
Matias Soncini
Gianluigi MazzoccoliGianluigi Mazzoccoli
Gianluigi Mazzoccoli
LFLidia De Filippis
Lidia De Filippis
Toll-like receptor 4 (TLR4) activation is pivotal to innate immunity and has been shown to regulate proliferation and differentiation of human neural stem cells (hNSCs) in vivo. Here we study the role of TLR4 in regulating hNSC derived from the human telencephalic-diencephalic area of the fetal brain and cultured in vitro as neurospheres in compliance with Good Manifacture Procedures (GMP) guidelines. Similar batches have been used in recent clinical trials in ALS patients. We found that TLR2 and 4 are expressed in hNSCs as well as CD14 and MD-2 co-receptors, and TLR4 expression is downregulated upon differentiation. Activation of TLR4 signaling by lipopolysaccharide (LPS) has a positive effect on proliferation and/or survival while the inverse is observed with TLR4 inhibition by a synthetic antagonist. TLR4 activation promotes neuronal and oligodendrocyte differentiation and/or survival while TLR4 inhibition leads to increased apoptosis. Consistently, endogenous expression of TLR4 is retained by hNSC surviving after transplantation in ALS rats or immunocompromised mice, thus irrespectively of the neuroinflammatory environment. The characterization of downstream signaling of TLR4 in hNSCs has suggested some activation of the inflammasome pathway. This study suggests TLR4 signaling as essential for hNSC self-renewal and as a novel target for the study of neurogenetic mechanisms.

29 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FCFlorent Cochet
Florent Cochet
FFFabio A. Facchini
Fabio A. Facchini
LZLenny Zaffaroni
Lenny Zaffaroni
JBJean-Marc Billod
Jean-Marc Billod
HCHelena Coelho
Helena Coelho
FPFrancesco Peri
Francesco Peri
New monosaccharide-based lipid A analogues were rationally designed through MD-2 docking studies. A panel of compounds with two carboxylate groups as phosphates bioisosteres, was synthesized with the same glucosamine-bis-succinyl core linked to different unsaturated and saturated fatty acid chains. The binding of the synthetic compounds to purified, functional recombinant human MD-2 was studied by four independent methods. All compounds bound to MD-2 with similar affinities and inhibited in a concentration-dependent manner the LPS-stimulated TLR4 signaling in human and murine cells, while being inactive as TLR4 agonists when provided alone. A compound of the panel was testedin vivoand was not able to inhibit the production of proinflammatory cytokines in animals. This lack of activity is probably due to strong binding to serum albumin, as suggested by cell experiments in the presence of the serum. The interesting self-assembly property in solution of this type of compounds was investigated by computational methods and microscopy, and formation of large vesicles was observed by cryo-TEM microscopy.

12 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FFFabio A. Facchini
Fabio A. Facchini
AMAlberto Minotti
Alberto Minotti
ALAndrea Luraghi
Andrea Luraghi
ARAlessio Romerio
Alessio Romerio
NGNicole Gotri
Nicole Gotri
FPFrancesco Peri
Francesco Peri
Modern adjuvants for vaccine formulations are immunostimulating agents whose action is based on the activation of pattern recognition receptors (PRRs) by well-defined ligands to boost innate and adaptive immune responses. Monophosphoryl lipid A (MPLA), a detoxified analogue of lipid A, is a clinically approved adjuvant that stimulates toll-like receptor 4 (TLR4). The synthesis of MPLA poses manufacturing and quality assessment challenges. Bridging this gap, we report here the development and preclinical testing of chemically simplified TLR4 agonists that could sustainably be produced in high purity and on a large scale. Underpinned by computational and biological experiments, we show that synthetic monosaccharide-based molecules (FP compounds) bind to the TLR4/MD-2 dimer with submicromolar affinities stabilizing the active receptor conformation. This results in the activation of MyD88- and TRIF-dependent TLR4 signaling and the NLRP3 inflammasome. FP compounds lack in vivo toxicity and exhibit adjuvant activity by stimulating antibody responses with a potency comparable to MPLA.

1 November 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
MPMateusz Pallach
Mateusz Pallach
Flaviana Di LorenzoFlaviana Di Lorenzo
Flaviana Di Lorenzo
FFFabio Alessandro Facchini
Fabio Alessandro Facchini
DGDjamel Gully
Djamel Gully
EGEric Giraud
Eric Giraud
Alba SilipoAlba Silipo
Alba Silipo
Acetobacter pasteurianus is an acetic acid-producing Gram-negative bacterium commonly found associated with plants and plant products and widely used in the production of fermented foods, such as kefir and vinegar. Due to the acid conditions of the bacterium living habitat, uncommon structural features composing its cell envelope are expected. In the present work we have investigated the A. pasteurianus CIP103108 lipopolysaccharide (LPS) structure and immunoactivity. The structure of the lipid A and of two different O-polysaccharides was assessed. Furthermore, immunological studies with human cells showed a low immunostimulant activity of the isolated LPS, in addition to a slight capability to lower the NF-kB activation upon stimulation by toxic LPS.

15 May 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSStefania E. Sestito
Stefania E. Sestito
FFFabio A. Facchini
Fabio A. Facchini
IMIlaria Morbioli
Ilaria Morbioli
JBJean-Marc Billod
Jean-Marc Billod
SMSonsoles Martin-Santamaria
Sonsoles Martin-Santamaria
FPFrancesco Peri
Francesco Peri